期刊文献+

EGFR基因在肺腺癌中突变的研究

Epidermal growth factor receptor mutation in lung adenocarcinoma
下载PDF
导出
摘要 目的:探讨表皮生长因子受体(EGFR)基因酪氨酸激酶域体细胞在肺腺癌患者中突变的相关因素。方法:分析和检测64例肺腺癌石蜡包埋标本EGFR基因突变状况,采用PCR和序列分析技术进行EGFR基因18、19和21外显子突变分析。结果:64例PAC患者中有16例(25%)酪氨酸激酶域存在体细胞突变。其中2例(3.1%)为18外显子,7例(10.93%)为19外显子,7例(10.93%)为21外显子。结论:肺腺癌(PAC)患者肿瘤组织中EGFR基因突变主要集中于19、21外显子突变,女性高于男性。 Objective: To study Somatic mutation of the tyrosine kinase(TK) domain of the epidermal growth factor receptor(EGFR gene) in lung adenocarcinoma patients.Methods: Mutational analysis for EGFR exons18,19,20 and 21 was performed in 64 patients.Results: Somatic mutations in TK domain of EGFR were identified in 16 of the 64(25%) patients,including 2 cases in exon 18(3.12%),7 cases in exon 19(10.93%) and 7 cases of in exon 21(10.93%).Conclusion: EGFR gene mutations is concentrate on 19 and 21 hot sport.The mutation rate of women is higher than that of men.
出处 《军医进修学院学报》 CAS 北大核心 2008年第6期520-522,共3页 Academic Journal of Pla Postgraduate Medical School
基金 科技部"中国人类遗传资源共享平台"项目(DKA30490) 军队"十一五"科研基金项目(06G106)
关键词 肺腺癌 表皮生长因子受体 突变 基因 lung adenocarcinoma receptor epidermal growth factor mutation gene
  • 相关文献

参考文献3

二级参考文献28

  • 1BaoMingQIN,XiaoCHEN,JingDeZHU,DuanQingPEI.Identification of EGFR kinase domain mutations among lung cancer patients in China:implication for targeted cancer therapy[J].Cell Research,2005,15(3):212-217. 被引量:66
  • 2管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量:114
  • 3Minna JD, Gazdar AF, Sprang SR, Herz J. Cancer. A bull's eye for targeted lung cancer therapy. Science 2004; 304:1458-61.
  • 4Dowell JE, Minna JD. Chasing mutations in the epidermal growth factor in lung cancer. N Engl J Med 2005; 352:830-2.
  • 5Tanovic A, Alfaro V. Gefitinib: current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 2004; 40:809-27.
  • 6Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004; 122:598-609.
  • 7Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy. Science2004; 304:1497-500.
  • 8Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
  • 9Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004; 10:8195-203.
  • 10Han SW, Kim TY, Hwang PG, et al. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in NonSmall-Cell Lung Cancer Patients Treated With Gefitinib. J Clin Oncol 2005; Feb 14: Epub ahead of print. http://dx.doi.org/10.1200/JCO.2005.01.388.

共引文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部